Statins and erectile dysfunction are often discussed in a way that creates more anxiety than clarity. Some men worry that cholesterol medication may impair sexual function, while others notice erectile dysfunction (ED) before they are ever prescribed a statin. The clinical evidence suggests a more nuanced interpretation: high cholesterol and vascular disease are established contributors to ED, while statins do not appear to meaningfully increase new-onset ED risk in controlled analyses and may improve erectile function in selected men with dyslipidemia.
Why Cholesterol and Erectile Function Are Connected
Erections depend on blood flow. Sexual stimulation triggers nitric oxide release in penile tissue, increasing cyclic guanosine monophosphate and relaxing smooth muscle in the corpora cavernosa. Blood then enters the penile arteries, the sinusoids expand, and venous outflow is restricted long enough to maintain rigidity.
That pathway is sensitive to endothelial health. The endothelium is the inner lining of blood vessels and is central to nitric oxide production. When low-density lipoprotein cholesterol, insulin resistance, hypertension, smoking, or inflammation damages the endothelium, penile blood flow can become impaired. Because penile arteries are relatively small, ED may appear before symptoms in larger coronary or peripheral arteries.
This is why ED is often treated as a cardiometabolic signal rather than an isolated sexual symptom. In men with elevated LDL cholesterol or broader cardiovascular risk, the underlying vascular environment may be contributing to both erectile function and long-term cardiac risk.
Do Statins Cause Erectile Dysfunction?
The concern is biologically understandable. Cholesterol is a precursor for steroid hormones, and statins lower cholesterol synthesis. Some reports have raised questions about testosterone, libido, and erectile symptoms in individual patients. Case reports and adverse-event databases can identify possible signals, but they cannot reliably separate medication effects from the underlying conditions that led to statin therapy in the first place.
A 2018 systematic review and meta-analysis in The American Journal of Medicine addressed the question directly by evaluating randomized trials and observational studies comparing statin users with non-users. Across 69,448 men, including 24,661 statin users, statin use was not associated with a statistically significant increase in new-onset erectile dysfunction. The authors also found no meaningful difference in treatment effect by age or diabetes status.
That does not mean no individual can experience sexual side effects. Individual tolerability varies with dose, medication type, comorbidities, and concurrent prescriptions. But at the population level, the best available evidence does not support the idea that statins broadly cause ED.
Why Statins May Improve ED in Some Men
Several analyses suggest that statins may improve erectile function when ED is linked to dyslipidemia and endothelial dysfunction. A 2014 meta-analysis of randomized trials in The Journal of Sexual Medicine found that statin therapy increased five-item International Index of Erectile Function scores by 3.4 points compared with control. A separate 2014 systematic review in Asian Journal of Andrology reported a similar direction of effect, with statins associated with improved IIEF-5 scores and improved lipid profiles.
The likely explanation is vascular rather than hormonal. Statins lower LDL cholesterol, reduce vascular inflammation, and can improve endothelial function. Better endothelial function can increase nitric oxide availability, which is central to erection physiology. In men whose ED is partly driven by impaired blood vessel function, improving the vascular substrate may support better response to arousal and to PDE5 inhibitor therapy.
The size of benefit should be interpreted carefully. Statins are not ED drugs, and they are not prescribed primarily to improve erections. Their strongest indication remains cardiovascular risk reduction. But when ED is part of a broader pattern of dyslipidemia and endothelial dysfunction, better lipid control may support sexual function as one part of systemic vascular improvement.
Evidence in PDE5 Inhibitor Nonresponders
One clinically important subgroup is men who respond incompletely to PDE5 inhibitors such as sildenafil or tadalafil. These medications preserve cyclic GMP signaling after nitric oxide is released, but they still require adequate upstream nitric oxide production and vascular responsiveness. If endothelial dysfunction is severe, PDE5 inhibition may have less signal to amplify.
In a randomized trial published in International Journal of Impotence Research, Dadkhah and colleagues studied 131 hypercholesterolemic men with ED who had not initially responded to sildenafil. Participants received either atorvastatin 40 mg daily or placebo for 12 weeks while continuing on-demand sildenafil. The study found that adjunctive atorvastatin improved erectile response compared with placebo in this selected group.
This does not prove that every man with ED should take a statin. It does suggest that lipid management can matter when ED is vascular and when response to PDE5 inhibition is incomplete. The clinical question is not "statin or ED medication?" but whether the vascular drivers of ED are being addressed alongside symptom-directed treatment.
What Men Should Not Do
Men should not stop a prescribed statin abruptly because of erectile concerns without speaking with a clinician. For many patients, statins reduce the risk of myocardial infarction, stroke, and other major cardiovascular events. Discontinuing treatment may increase cardiovascular risk, especially in men with established atherosclerotic disease, diabetes, or high calculated risk.
It is also not useful to assume that a new erection problem is caused by the most recent medication. ED is multifactorial. Sleep deprivation, alcohol use, depression, relationship stress, testosterone deficiency, hypertension, diabetes, obesity, pelvic surgery, and other prescriptions can all contribute. A medication timeline is relevant, but it should be interpreted within a broader clinical assessment.
If symptoms begin after starting or increasing a statin, a clinician can review dose, statin type, drug interactions, testosterone symptoms, and cardiovascular risk. Sometimes a medication adjustment is reasonable. Sometimes the more important finding is that ED has revealed an underlying vascular problem that needs more attention, not less.
Practical Clinical Interpretation
For men with both ED and elevated cholesterol, the most evidence-consistent interpretation is that vascular risk management and ED treatment should be coordinated. Lipid testing, blood pressure measurement, hemoglobin A1c, medication review, sleep assessment, and lifestyle factors can clarify whether ED is functioning as an early cardiometabolic signal.
PDE5 inhibitors remain first-line prescription therapy for many men with ED, but they work best when the underlying physiology can support nitric oxide signaling and penile blood flow. A man with untreated hypertension, poorly controlled diabetes, or high LDL cholesterol may experience partial response until those drivers are addressed.
Statins may therefore be relevant to ED in two ways. First, they do not appear to increase new-onset ED risk at the population level. Second, in men with dyslipidemia and vascular ED, they may modestly improve erectile function or improve response to PDE5 inhibitors by supporting endothelial health. That is a clinical rationale for treating cholesterol appropriately, not a reason to use statins as a standalone ED intervention.
Conclusion
Statins and erectile dysfunction should be viewed through the lens of vascular health. The evidence does not support a broad claim that statins cause ED, and several randomized-trial meta-analyses suggest they may improve erectile function in men with dyslipidemia or endothelial dysfunction. ED can also be an early warning sign of cardiometabolic disease, making cholesterol evaluation and cardiovascular risk reduction clinically relevant. For more evidence-based men's health topics, visit the /blog archive.
If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans, including Red Pill, starting with a free online assessment at questionnaire.getonyxmd.com.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
- Kostis JB, Dobrzynski JM. The effect of statins on erectile dysfunction: a meta-analysis of randomized trials. The Journal of Sexual Medicine. 2014;11(7):1626-1635. doi:10.1111/jsm.12521
- Cai X, Tian Y, Wu T, Cao CX, Bu SY, Wang KJ. The role of statins in erectile dysfunction: a systematic review and meta-analysis. Asian Journal of Andrology. 2014;16(3):461-466. PMCID: PMC4023379
- Cui Y, Zong H, Yan H, Zhang Y. The effect of statins on erectile dysfunction: a systematic review and meta-analysis. The Journal of Sexual Medicine. 2014;11(6):1367-1375. doi:10.1111/jsm.12497
- Elgendy AY, Elgendy IY, Mahmoud AN, Al-Ani M, Moussa M, Mahmoud A, Mojadidi MK, Anderson RD. Statin use in men and new onset of erectile dysfunction: a systematic review and meta-analysis. The American Journal of Medicine. 2018;131(4):387-394. doi:10.1016/j.amjmed.2017.10.043
- Dadkhah F, Safarinejad MR, Asgari MA, Hosseini SY, Lashay A, Amini E. Atorvastatin improves the response to sildenafil in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafil. International Journal of Impotence Research. 2010;22(1):51-60. doi:10.1038/ijir.2009.48
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.